Korea’s Government-Funded Venture into Oncology
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Address: Room A-101, Namsong Bldg., 260-199 Itaewon-dong, Yongsan-gu Seoul, 140-200, Republic of Korea
Tel: +82 2 796 1056
Web: http://crm.cegedim.com/Pages/default.aspx
Cegedim was created in 1969 by Jean-Claude Labrune, a French visionary entrepreneur who focused on the pharmaceutical industry to provide companies with tailored services that help them build successful commercial strategies. In the late 70’s the first Customer Relationship Management solution designed for the Pharmaceutical industry was launched in France and quickly became a standard. With the success of its solutions, Cegedim quickly expanded its business internationally. In May 2007, Cegedim reinforced its global presence and leadership with the acquisition of Dendrite International, a US based company leading the SFA business in the healthcare sector on its continent as well as in Asia. This successful integration gave birth to a uniquely capable global entity providing Life Sciences ready CRM solutions. Today the new company renamed Cegedim Relationship Management does business in over 80 countries and accounts for more than 50 percent of the Cegedim Group’s annual revenues of $1.1 billion. Around the world, Cegedim Relationship Management works with companies behind the scenes to develop the most appropriate solutions that effectively manage the complex regulatory environment, minimize risks and decrease costs. Laurent Labrune, Group founder’s son, is the Chief Executive Officer of the new global organisation since 2007. He brought a wealth of creativity, innovation and expertise with a strong and knowledgeable management team. Altogether, they effectively made strategic choices for the long term leadership of the company.
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…
Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of…
Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology…
JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of…
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
See our Cookie Privacy Policy Here
